我們已在上線! 進一步了解
CWBR

CohBar, Inc. Common Stock

已下市

CWBR已於2023年11月28日下市。

 

關於: CohBar Inc is a biotechnology company. It is engaged in the research and development of mitochondria-based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. The product portfolio of the company includes drugs such as CB4209 and CB4211, SHLP-6, SHLP-2, and new MBTs, these address a broad range of age-related diseases, including obesity, fatty liver disease, Type-2 diabetes, cancer, cardiovascular and neurodegenerative diseases. Geographically all the operations of the group functioned through the region of the United States.

員工: 10

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%
價格圖表採用Lightweight Charts™實作